Extracorporeal membrane oxygenation (ECMO) in patients with tuberculosis: systematic review and meta-analysis of 43 cases

• Published in: BMC pulmonary medicine Vol. 24; no. 1; pp. 47 - 10
• Main Authors: Idris, Raja, Zielbauer, Ann-Sophie, Koepsell, Julia, Kloka, Jan, Wetzstein, Nils
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 22-01-2024; BioMed Central; BMC
• Subjects: Adolescent; Adult; Aged; Antitubercular agents; Blood oxygenation, Extracorporeal; Care and treatment; Child; Child, Preschool; Coinfection; Comorbidity; COVID-19; Diagnosis; Dosage and administration; ECMO; Extracorporeal Membrane Oxygenation; Female; Humans; Infant; Infant, Newborn; Literature reviews; Male; Meta-analysis; Middle Aged; Mortality; Oxygenation; Patient outcomes; Patients; Public health; Respiratory Insufficiency - etiology; Respiratory Insufficiency - therapy; Tuberculosis; Tuberculosis, Pulmonary - complications; Tuberculosis, Pulmonary - therapy; Young Adult; Germany; ECMO; Extracorporeal membrane oxygenation; Tuberculosis; TB
• ISSN: 1471-2466; 1471-2466
• DOI: 10.1186/s12890-023-02715-x

Tuberculosis (TB) is still a major contributor to the global health burden. Pulmonary TB can lead to life-threatening respiratory failure necessitating extracorporeal membrane oxygenation (ECMO) therapy. However, data on ECMO experience in the management of TB patients are scarce.
We conducted a systematic review of the literature using the search terms ECMO, extracorporeal membrane oxygenation, TB and tuberculosis in three databases (Medline, Web of Science and EMBASE). Clinical data were extracted by two independent investigators. Clinical parameters, such as mode of ECMO therapy, duration of treatment and clinical outcomes, were assessed.
Overall, 43 patients from 15 countries were included in the analysis. The age ranged from 0 to 65 years, 39.5% were male, and 60.5% were female. The majority of patients suffered from ARDS (83.4%), with a mean Horovitz quotient of 68.1 (range 30.0-131.0). 83.7% received VV-ECMO, and 24.3% received VA-ECMO. Coinfections and complications were frequently observed (45.5% and 48.6% respectively). At the end of the respective observation period, the overall outcome was excellent, with 81.4% survival.
ECMO therapy in TB patients appears to be a feasible therapeutic option, providing a bridge until antimycobacterial therapy takes effect. As the underlying cause is reversible, we advocate for the evaluation of ECMO usage in these patients with acute cardiac or respiratory failure.